Mr. James Durward reports

NDATALYZE CORP. ("NDAT" OR THE "CORPORATION") (CSE:NDAT) (OTC:NDATF) ANNOUNCES A LETTER OF INTENT WITH A PHARMACOGENETICS COMPANY

On Nov. 8, 2023, nDatalyze Corp. signed a letter of intent (LOI) with Personalized Prescribing (PP), which LOI contemplates the addition of a DNA adjunct to nDatalyze's previously announced clinical study. The LOI anticipates a final agreement within 30 days, which agreement is to include PP's provision of existing DNA data for up to 200 participants in the 18-to-29-year age group. It is expected that participants will complete nDatalyze's biometric questionnaire, with the answers combined with associated DNA data for submission to a machine-learning correlation process that is already planned for machine-learning aspect of the clinical study. Participants will be compensated by nDatalyze at a modest rate typical for this type of non-invasive survey.

James Durward, chief executive officer and chief technology officer, states: "We've always had DNA expressions in our database and we've always envisioned the addition of raw DNA data that may be used as support correlation for our mental condition predictions. This relationship provides multiple tangible and intangible benefits, including access to an existing DNA database where we can solicit questionnaire enrolment without having to pay the costs of DNA tests. Furthermore, PP has deep knowledge of DNA-related drug interactions and this may fit well with our goal of not only reducing misdiagnosis, but also reducing misprescriptions that often lead to poor outcomes and lower overall societal mental health."

About Personalized Prescribing: Personalized Prescribing is committed to developing world-leading pharmacogenetic algorithms and technology to ensure individuals receive the right drug, in the right dose, without suffering through months and often years of drug failure and unnecessary side effects. Its motto is: "Create a new standard of patient care in psychiatry that is based on objective data and clear science." Personalized Prescribing's genetic tests are covered by multiple health benefits providers.

About YMI: YMI uses evidence-based, objective data from whole-life experiences to predict individual mental states over time, and applies this knowledge toward a fuller understanding of how mental health develops and to improve mental well-being. YMI combines machine-learning with a proprietary reference database that contains more than 1,200 person's genetic expressions, childhood environment, habits, phobias, lived experiences and lifestyles to generate a personalized graphic report predicting an individual's predisposition toward a variety of common mental conditions, both current and forward in time.

We seek Safe Harbor.